R. Hollingsworth

发表

Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.

E. Sanders, M. Bonten, C. H. van Werkhoven, 2016, Vaccine.

Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV).

A. Lloyd, A. Lloyd, P. Conway, 2005, Vaccine.

Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial.

A. Shrestha, M. Dupuy, I. D. de Bruijn, 2021, American heart journal.

Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact

Anne C. Beal, Thomas R Quisel, L. Foschini, 2019, Journal of diabetes science and technology.

Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): The 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness.

A. Palache, R. Hollingsworth, T. Tsai, 2017, Vaccine.

Noninvasive Streptococcus pneumoniae Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012

Ronald N. Jones, D. Farrell, R. Isturiz, 2015, Antimicrobial Agents and Chemotherapy.

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

P. S. Leventhal, I. D. de Bruijn, Stéphanie Pépin, 2018, Expert review of vaccines.

Pneumococcal vaccination of older adults

R. Isturiz, R. Hollingsworth, 2013, Human vaccines & immunotherapeutics.

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis

P. S. Leventhal, D. Greenberg, S. Samson, 2019, Expert review of vaccines.

The stubborn persistence of adult pneumococcal pneumonia as a public health problem

R. Isturiz, R. Hollingsworth, 2014, Human vaccines & immunotherapeutics.

Introductory paper: High dose influenza vaccine.

A. Chit, M. Mercer, D. Greenberg, 2021, Vaccine.

Cost-effectiveness analysis has to consider all available evidence when informing inputs

Audrey Petitjean, Fabián P Alvarez, Joshua Nealon, 2020, Human vaccines & immunotherapeutics.

Assessment of the benefits of seasonal influenza vaccination: Elements of a framework to interpret estimates of vaccine effectiveness and support robust decision‐making and communication

R. Hollingsworth, H. Bright, T. Tsai, 2020, Influenza and other respiratory viruses.

Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective.

A. Chit, S. Gurunathan, S. Sridhar, 2020, Contemporary clinical trials.

PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCVI3) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK

A. Lloyd, B. Stoykova, R. Hollingsworth, 2009 .